Drug intelligence / Profile preview

11C-CFT

Development stage
Unknown
Lead developer
Luye Pharma
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

11C-CFT is a radiopharmaceutical used as a positron emission tomography (PET) tracer to visualize and quantify the dopamine transporter (DAT) in the brain. It is a cocaine analog that binds with high affinity and selectivity to presynaptic DAT, primarily located in the striatum (caudate and putamen). By measuring DAT density, 11C-CFT PET imaging serves as a biomarker for the integrity of nigrostriatal dopaminergic neurons. It is extensively used in clinical research and diagnosis to differentiate Parkinson's disease from other movement disorders, assess disease progression, and evaluate the occupancy of dopamine transporters by therapeutic drugs like toludesvenlafaxine. The tracer is typically produced in-house by facilities equipped with a cyclotron due to the short half-life of the Carbon-11 isotope.

Other names
11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane11C-methyl-N-2β-carbomethoxy-3β-(4-fluorophenyl)-tropane[11C]CFT11C-WIN 354282β-carbomethoxy-3β-(4-fluorophenyl) tropane
02

Targets

DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on 11C-CFT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11C-CFT.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call